Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 15 June 2007, Vol. 109, No. 12, pp. 5407-5410.
Prepublished online as a Blood First Edition Paper on March 9, 2007; DOI 10.1182/blood-2006-08-039446.

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
blood-2006-08-039446v1
109/12/5407    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Popescu, M. C.
Right arrow Articles by Kwak, L. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Popescu, M. C.
Right arrow Articles by Kwak, L. W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Next Article next article arrow

Submitted August 7, 2006
Accepted February 26, 2007

A novel proteoliposomal vaccine elicits potent anti-tumor immunity in mice

Mircea C. Popescu*, Richard J. Robb, Michael M. Batenjany, Lawrence T. Boni, Mary E. Neville, Robin W. Pennington, Sattva S. Neelapu, and Larry W. Kwak

Biomira USA, Inc., Cranbury, NJ, United States
XEME Biopharma, Inc., Plainsboro, NJ, United States
Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, United States
Department of Lymphoma and Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States

* Corresponding author; email: mpopescu{at}xemebiopharma.com.

Therapeutic vaccination against idiotype is a promising strategy for immunotherapy of B-cell malignancies. Its feasibility, however, is limited by the requirement for a patient-specific product. Here we describe a novel vaccine formulation prepared by simply extracting cell membrane proteins from lymphoma cells and incorporating them together with IL-2 into proteoliposomes. Vaccine was produced in 24h, compared with more labor-intensive and time-consuming hybridoma or recombinant DNA methods. The vaccine elicited T-cell immunity in vivo as demonstrated by secretion of type 1 cytokines. It protected against tumor challenge at doses of tumor antigen 50 to 100 times lower than that previously observed using either liposomes formulated with IL-2 and secreted lymphoma immunoglobulin or a prototype vaccine consisting of lymphoma immunoglobulin conjugated to keyhole limpet hemocyanin. The increased potency justifies testing of similar patient-specific human vaccines prepared using extracts from primary tumor samples.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 ASH Education BookHome page
S. S. Neelapu and L. W. Kwak
Vaccine Therapy for B-Cell Lymphomas: Next-Generation Strategies
Hematology, January 1, 2007; 2007(1): 243 - 249.
[Abstract] [Full Text] [PDF]


click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020